Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer, Cancer

In brief

This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.

Key facts

Study ID

NCT03403049

Run by

Montefiore Medical Center

People needed

14

Starts

2016-04-01

Expected to finish

2019-07-09

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed the informed consent form;
• Age ≥ 18;
• Capable of following the protocol
• Cytologically or histologically proven diagnosis of adenocarcinoma of the pancreas;
• Unresectable adenocarcinoma of the pancreas by radiographic criteria according to the criteria of the NCCN Guidelines and based on post-chemotherapy imaging or due to medical contraindications to radical resection;
• No evidence of distant metastases based on imaging evaluation;
• Maximum tumor and positive lymph node diameter ≤ 6 cm;
• ECOG Performance Status 0-1;
• Life expectancy ≥ 12 weeks;
• Adequate blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥100 x 109/L, and hemoglobin ≥9 g/dL (use of transfusion to achieve said levels or greater is acceptable);
• Adequate liver function: total bilirubin <1.5 x ULN, and AST and ALT <2.5 x ULN;
• Adequate kidney function: serum creatinine ≤1.25 x ULN or calculated creatinine clearance rate ≥50mL/min and urine protein <2+.If the patient's baseline urine protein is at ≥2+, urine samples must be taken for 24 hours to verify that urine protein is ≤1g;
• Laboratory studies within 14 days prior to registration demonstrating that the internationalization standard ratio (INR) ≤1.5 and prothrombin time (PPT) ≤1.5 x ULN.
• Prior receipt of 2-4 cycles of Gemcitabine-based systemic chemotherapy.

You may not qualify if…

• Lack of pathologic confirmation of pancreatic malignancy prior to treatment initiation;
• ECOG Performance Status >=2;
• Poor liver, kidney and bone marrow function that do not meet the requirements for treatment;
• Persistent grade ≥ 2 toxicity due to previous cancer treatment;
• Patient has previously received abdominal radiation therapy or abdominal radioactive seed implantation;
• Those wearing a cardiac pacemaker or another type of metal prosthetic implant whose normal functions may suffer interference from high energy radiation or that could affect the radiation target area;
• Where it is not possible to achieve the predetermined safety dose limit with the dose equivalent limit of the organ at risk such as the liver or digestive tract, etc.;
• If the doctor determines that the heavy proton or carbon ion dosage radiotherapy will not bring any benefit to the patient;
• Patients suffering from another illness or other factors that could affect the proton or carbon ion therapy;
• Pregnant (verified by serum or urine β-HCG test) or breastfeeding females;
• Drug-abuse or alcohol dependency;
• HIV positive, including those that have received antiretroviral therapy; replicative stage of chronic Hepatitis B virus; active stage of Hepatitis C; and active stage of syphilis;
• HBV positive patients suffering from replicative stage of hepatitis virus, requiring antiretroviral therapy but cannot due to a concomitant disease;
• Patients with a history of mental illness that may prevent their completion of treatment;
• Patients with serious complications that could affect the course of treatment, including:
• Unstable angina, congestive heart failure, or myocardial infarction requiring hospital admittance over the last 6 months;
• Acute or systemic bacterial infection;
• Chronic exacerbated obstructive pulmonary disease or other respiratory system disease requiring inpatient treatment;
• Impaired liver function or impaired kidney function;
• Patients suffering from immunosuppression;
• Patients with contraindications to receiving radiotherapy, such as a serious connective tissue disease (eg: scleroderma)
• Patients that are unable to understand the objective of the treatment/cannot sign the informed consent form;
• Patients that lack civil capacity to act or whose civil capacity to act is limited.

Where it is running

• Albert Einstein College of Medicine — The Bronx, New York, United States
• Shanghai Proton and Heavy Ion Center — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.